Saslow Debbie, Boetes Carla, Burke Wylie, Harms Steven, Leach Martin O, Lehman Constance D, Morris Elizabeth, Pisano Etta, Schnall Mitchell, Sener Stephen, Smith Robert A, Warner Ellen, Yaffe Martin, Andrews Kimberly S, Russell Christy A
Cancer Control Science Department, American Cancer Society, Atlanta, GA, USA.
CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. doi: 10.3322/canjclin.57.2.75.
New evidence on breast Magnetic Resonance Imaging (MRI) screening has become available since the American Cancer Society (ACS) last issued guidelines for the early detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed new recommendations for women at different defined levels of risk. Screening MRI is recommended for women with an approximately 20-25% or greater lifetime risk of breast cancer, including women with a strong family history of breast or ovarian cancer and women who were treated for Hodgkin disease. There are several risk subgroups for which the available data are insufficient to recommend for or against screening, including women with a personal history of breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mammography. Diagnostic uses of MRI were not considered to be within the scope of this review.
自美国癌症协会(ACS)上次于2003年发布乳腺癌早期检测指南以来,关于乳腺磁共振成像(MRI)筛查的新证据已经出现。一个指南小组审查了这些证据,并针对不同定义风险水平的女性制定了新的建议。对于乳腺癌终生风险约为20%-25%或更高的女性,建议进行MRI筛查,包括有乳腺癌或卵巢癌家族史的女性以及接受过霍奇金病治疗的女性。有几个风险亚组,现有数据不足以推荐或反对进行筛查,包括有乳腺癌个人史、原位癌、非典型增生以及乳腺钼靶检查显示乳腺极度致密的女性。MRI的诊断用途不在本次审查范围内。